Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.

Lane JA, Er V, Avery KNL, Horwood J, Cantwell M, Caro GP, Crozier A, Smith GD, Donovan JL, Down L, Hamdy FC, Gillatt D, Holly J, Macefield R, Moody H, Neal DE, Walsh E, Martin RM, Metcalfe C.

Cancer Prev Res (Phila). 2018 Nov;11(11):687-696. doi: 10.1158/1940-6207.CAPR-18-0147. Epub 2018 Oct 11.

PMID:
30309839
2.

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group.

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582. Epub 2016 Aug 17.

3.

Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.

Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, I Walsh E, Hill EM, Down L, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Davies CF, Ng SY, Neal DE, Hamdy FC, Albertsen P, Reid CM, Oxley J, McFarlane J, Robinson MC, Adolfsson J, Zietman A, Baum M, Koupparis A, Martin RM.

Br J Cancer. 2016 Jun 28;115(1):90-4. doi: 10.1038/bjc.2016.162. Epub 2016 Jun 2.

4.

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Thorn JC, Turner EL, Hounsome L, Walsh E, Down L, Verne J, Donovan JL, Neal DE, Hamdy FC, Martin RM, Noble SM; CAP trial group.

BMJ Open. 2016 Apr 29;6(4):e011063. doi: 10.1136/bmjopen-2016-011063.

5.

Hemodynamics of the renal artery ostia with implications for their structural development and efficiency of flow.

McIntosh WH, Ozturk M, Down LA, Papavassiliou DV, O'Rear EA.

Biorheology. 2015;52(4):257-68. doi: 10.3233/BIR-15069.

PMID:
26639358
6.

Validation of The Hospital Episode Statistics Outpatient Dataset in England.

Thorn JC, Turner E, Hounsome L, Walsh E, Down L, Donovan J, Verne J, Neal D, Hamdy F, Martin RM, Noble S.

Value Health. 2014 Nov;17(7):A547-8. doi: 10.1016/j.jval.2014.08.1778. Epub 2014 Oct 26. No abstract available.

7.

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy FC; ProtecT study group.

Lancet Oncol. 2014 Sep;15(10):1109-18. doi: 10.1016/S1470-2045(14)70361-4. Epub 2014 Aug 19. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

8.

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, Avery KN, Down L, Walsh E, Davis M, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Hill EM, Davies C, Ng SY, Neal DE, Hamdy FC, Martin RM; CAP trial group.

Br J Cancer. 2014 Jun 10;110(12):2829-36. doi: 10.1038/bjc.2014.242. Epub 2014 May 27.

9.

Arterial deformation with renal artery aneurysm as a basis for secondary hypertension.

Down LA, Papavassiliou DV, O'Rear EA.

Biorheology. 2013;50(1-2):17-31. doi: 10.3233/BIR-130623.

PMID:
23619150
10.

Men with prostate cancer make positive dietary changes following diagnosis and treatment.

Avery KN, Donovan JL, Gilbert R, Davis M, Emmett P, Down L, Oliver S, Neal DE, Hamdy FC, Lane JA.

Cancer Causes Control. 2013 Jun;24(6):1119-28. doi: 10.1007/s10552-013-0189-x. Epub 2013 Mar 22.

PMID:
23519639
11.

Effects of gamma radiation on a ventricular assist device and its percutaneous lead components.

Chelikani NM, Masterson K, Down LA, Gill RS, Farar DJ, Horstmanshof DA, Long JW, Snyder TA.

ASAIO J. 2012 Jan-Feb;58(1):19-24. doi: 10.1097/MAT.0b013e31823e5bcc.

PMID:
22210647
12.

Clinicopathological and molecular study of penile melanoma.

Oxley JD, Corbishley C, Down L, Watkin N, Dickerson D, Wong NA.

J Clin Pathol. 2012 Mar;65(3):228-31. doi: 10.1136/jclinpath-2011-200344. Epub 2011 Oct 19.

PMID:
22011445
13.

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.

Down L, Metcalfe C, Martin RM, Neal DE, Hamdy FC, Donovan JL, Lane JA.

BJU Int. 2011 Nov;108(9):1409-14. doi: 10.1111/j.1464-410X.2011.10174.x. Epub 2011 Mar 31.

14.

Significance of extensional stresses to red blood cell lysis in a shearing flow.

Down LA, Papavassiliou DV, O'Rear EA.

Ann Biomed Eng. 2011 Jun;39(6):1632-42. doi: 10.1007/s10439-011-0262-0. Epub 2011 Feb 5.

PMID:
21298343
15.

A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance.

Lane JA, Wade J, Down L, Bonnington S, Holding PN, Lennon T, Jones AJ, Salter CE, Neal DE, Hamdy FC, Donovan JL; ProtecT Study Team.

J Clin Epidemiol. 2011 Jun;64(6):628-36. doi: 10.1016/j.jclinepi.2010.10.003. Epub 2011 Jan 15.

PMID:
21239142
16.

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).

Murad AS, Down L, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC, Neal DE, Martin RM.

Int J Cancer. 2011 Mar 15;128(6):1442-8. doi: 10.1002/ijc.25465.

17.

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.

Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K; ProtecT Study Group.

Br J Cancer. 2010 Apr 27;102(9):1335-40. doi: 10.1038/sj.bjc.6605648. Epub 2010 Apr 6.

18.

Psychological distress and prostate specific antigen levels in men with and without prostate cancer.

Turner EL, Lane JA, Metcalfe C, Down L, Donovan JL, Hamdy F, Neal D, Vedhara K.

Brain Behav Immun. 2009 Nov;23(8):1073-8. doi: 10.1016/j.bbi.2009.01.009. Epub 2009 Jan 22.

PMID:
19486654
19.

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?

Macefield RC, Lane JA, Metcalfe C, Down L, Neal DE, Hamdy FC, Donovan JL.

Eur J Cancer. 2009 Sep;45(14):2569-73. doi: 10.1016/j.ejca.2009.03.016. Epub 2009 Apr 16.

PMID:
19375907
20.

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified.

Down L, Metcalfe C, Avery K, Noble S, Lane JA, Neal DE, Hamdy FC, Donovan JL.

J Clin Epidemiol. 2009 Jan;62(1):67-73. doi: 10.1016/j.jclinepi.2008.02.014. Epub 2008 Jul 10.

PMID:
18619796
21.

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.

Lane JA, Howson J, Donovan JL, Goepel JR, Dedman DJ, Down L, Turner EL, Neal DE, Hamdy FC.

BMJ. 2007 Dec 1;335(7630):1139. Epub 2007 Nov 15.

22.

An early developmental role for eph-ephrin interaction during vertebrate gastrulation.

Oates AC, Lackmann M, Power MA, Brennan C, Down LM, Do C, Evans B, Holder N, Boyd AW.

Mech Dev. 1999 May;83(1-2):77-94.

23.

CDKN2A/p16 is inactivated in most melanoma cell lines.

Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK.

Cancer Res. 1997 Nov 1;57(21):4868-75.

24.

On the Relation of the Teeth and Mouth to Mental Development.

Down L.

Am J Dent Sci. 1872 Jun;6(2):64-73. No abstract available.

Supplemental Content

Support Center